RBC Europe’s Vertex Pharmaceuticals VRTX Stock Holding History

RBC Europe’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-280	Closed	-$50.8K	–	1150
2021 Q3	$50.8K	Hold	280	–	–	﹤0.01%	566
2021 Q2	$56.5K	Hold	280	–	–	﹤0.01%	564
2021 Q1	$60.2K	Sell	280 -145	-34%	-$31.8K	﹤0.01%	513
2020 Q4	$100K	Buy	425 +385	+963%	+$88.3K	0.01%	387
2020 Q3	$10.9K	Hold	40	–	–	﹤0.01%	780
2020 Q2	$11.6K	Hold	40	–	–	﹤0.01%	743
2020 Q1	$9.52K	Hold	40	–	–	﹤0.01%	721
2019 Q4	$8.76K	Buy	+40	New	+$8.1K	﹤0.01%	823
2019 Q3	–	Sell	-85	Closed	-$15.6K	–	1082
2019 Q2	$15.6K	Hold	85	–	–	﹤0.01%	702
2019 Q1	$15.6K	Hold	85	–	–	﹤0.01%	709
2018 Q4	$14.1K	Hold	85	–	–	﹤0.01%	714
2018 Q3	$16.4K	Hold	85	–	–	﹤0.01%	730
2018 Q2	$14.4K	Hold	85	–	–	﹤0.01%	758
2018 Q1	$13.9K	Buy	+85	New	+$13.9K	﹤0.01%	753

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

RBC Europe's VRTX Position: Q4 2021 in Review

RBC Europe sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 280 shares — an estimated $50.8K sold.

RBC Europe first reported a position in VRTX in Q1 2018 and held it in 14 quarters. The position peaked at $100K in Q4 2020. 1,033 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

RBC Europe reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 280 Vertex Pharmaceuticals shares in Q4 2021, an estimated $50.8K.
RBC Europe first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 14 quarters.
RBC Europe's Vertex Pharmaceuticals position peaked at $100K in Q4 2020.
1,033 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.